MediWound Ltd. (MDWD) Reports Q3 Revenue of $3.6M; 2026 Outlook Depends on U.S. Funding Talks
MediWound reported Q3 2026 revenue of $3.6M. It expects the EscharEx Phase III trial interim assessment and enrollment completion by end-Q1 2027; 2026 revenue recognition depends on uncertain U.S. government funding discussions.Material DetailsContext by AI AnalystThis is an ongoing late-stage clin…